Skip to main content
TipRanks
Go Ultimate75% OFF

Basma Radwan Profile - Leerink Partners Analyst

11 Followers

Basma Radwan's Stock Coverage

RYTM
Rhythm Pharmaceuticals
Sep 14, 2026BUYInitiated$133.001Ratings100%+2.50%
PTCT
PTC Therapeutics
Sep 14, 2026BUYInitiated$98.001Ratings0%-1.20%
LRMR
Larimar Therapeutics
Sep 14, 2026BUYReiterated$13.001Ratings0%-38.60%

Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed. See how TipRanks ranks experts and calculates performance.

Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >

Basma Radwan activity FAQ

What is the performance of Basma Radwan's recommendations?
The percentage of profitable recommendations made by Basma Radwan is 33.33%, and the average return per transaction is -12.40%.
What stocks does Basma Radwan cover?
Basma Radwan mostly covers Larimar Therapeutics, PTC Therapeutics, Rhythm Pharmaceuticals stocks.
What was Basma Radwan's most profitable rating?
Basma Radwan’s most profitable rating was a buy on Rhythm Pharmaceuticals stock on Sep 14, 2026. The return on the trade was 2.50%.
Where can I see a list of stock analyst ratings?
You can see a list of daily stock analyst ratings here.
What are the most recommended stocks by analysts?
You can see a list of the most recommended stocks by analysts here